Nov 11, 2014
Cellectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights
Oct 15, 2014
Cellectar Biosciences Announces Publication of Findings Demonstrating Efficacy of Its Phospholipid Ether Analog Platform in Detecting Colorectal Cancer
Cellectar’s product candidates are built on a novel, cancer and cancer stem cell-targeting delivery and retention platform of optimized phospholipid ether analogs (PLEs). We have shown that PLEs become trapped in malignant tumor cell membranes because tumor cells cannot metabolize and eliminate them.
Cellectar is developing a portfolio of imaging and therapeutic agents that capitalize on the unique attributes of its cancer-targeting technology. Because of the variety of agents that preclinical data suggest can be effectively linked to Cellectar’s phospholipid ether (PLE) delivery and retention platform, the opportunities for development span a broad range of uses and indications.